Explore the Agenda
7:30 am Registration Opens & Morning Coffee
8:20 am Chair’s Opening Remarks
Driving Translational & Strategic Success by Leveraging Investment & Next Generation Insights to Fast-Track LNP Development
8:30 am Keynote Presentation: Engineering of the Immune System
- Advancing Chimeric Antigen Receptor T-cell therapies: lessons learned from ex vivo engineered CAR T cell products
- Paving the way to in vivo generation of CAR-expressing immune cells: experience to date including viral and RNA-LNP based approaches
- The future of immunotherapy: bringing together precision medicine and nanotechnologies to advance safe, potent and tunable treatments for a broad range of disease categories
9:00 am Session Reserved for Serina Therapeutics
9:30 am Panel Discussion: Navigating Strategic Investments by Harnessing Insights from Recent Acquisitions & Collaborations within the LNP Field
- What are the driving factors behind recent deals, what are the unique aspects of LNP technology that investors are most focused on?
- What key factors do investors evaluate when assessing the potential and risks of LNP technologies?
- Beyond individual drug candidates, how do investors envision the broader potential and future impact of these LNP partnerships?
10:00 am Morning Break & Speed Networking
This session is your opportunity to get face-to-face with many of the brightest minds working in the LNP field and establish meaningful business relationships to pursue for the rest of the conference. Also, don’t forget to enjoy some refreshments before we split off into 3 different tracks: Analytical Development & Characterization, Formulation & Delivery and Process Development & Manufacturing.
Analytical Development & Characterization
Formulation & Delivery
Process Development & Manufacturing
Analytical Development & Characterization
Chair – Lokesh Narsineni, Senior Scientist, Process Sciences, Scribe Therapeutics
Leveraging Heightened Characterization Methods to Optimize LNP Morphology & Encapsulation for Improved Quality
11:00 am Molecular Characterization of Lipid Nanoparticles & mRNA Packaging with Single Particle Charge Detection Mass Spectrometry
Professor, University of California, Berkeley
- Description of new mass spectrometry technology for analysis of intact particles with masses ranging from kDa to GDa
- Applications to lipid nanoparticles to obtain accurate size distributions and mRNA packing
- Fast characterization of lipid nanoparticle stability and future developments
NEW DATA
NEW COMPANY
11:30 am Session Reserved for Spectradyne
12:00 pm Unravelling the Intricate Interplay Between LNP-RNA Properties Influencing the Structure & Morphological Features of LNPs
Senior Scientist, Process Sciences, Scribe Therapeutics
- Impact of LNP composition and pKa on the LNP structure, morphology and distribution of the RNA
- Influence of the RNA cargo size on the distribution of RNA, structure and morphology of LNPs and leveraging LNP formulation process to achieve desirable LNP characteristics
- Effect of RNA modifications on the structural and morphology features of an LNPs
NEW DATA
Formulation & Delivery
Process Development & Manufacturing
12:30 pm Lunch & Networking Break
Analytical Development & Characterization
Formulation & Delivery
Process Development & Manufacturing
Analytical Development & Characterization
Advancing Potency Assessment to Improve In Vitro/In Vivo Translation to Accelerate LNP Clinical Development
1:30 pm Precision RNA Delivery: AI-Guided Lipid & Nanoparticle Formulation with DNA Barcoding
Chief Executive Officer & Co-Founder, Barcode Nanotech
- Dual Machine Learning-Driven Optimization: Barcode Nanotech integrates two specialized machine learning models, one for lipid design and another for nanoparticle formulation, to systematically optimize RNA delivery vehicles. This approach enables precise tailoring of LNPs to target specific cell types across diverse tissues, enhancing therapeutic efficacy and reducing off-target effects
- High-Throughput In Vivo Screening with DNA Barcoding: Using a proprietary DNA barcode system, Barcode Nanotech can simultaneously test up to 100 LNP formulations in a single animal. Each formulation is uniquely tagged, allowing for accurate quantification of delivery efficiency across multiple organs and cell types, accelerating discovery and validation
- Data-Driven Formulation and Structure Insights: The platform generates rich, multidimensional datasets that link lipid chemistry, nanoparticle architecture, and biological performance. These result in iterative design cycles, enabling the refinement of both lipid structures and nanoparticle formulations to achieve optimal RNA delivery profiles
NEW COMPANY
2:00 pm Session Reserved for Satorius
2:30 pm Fireside Chat: Bridging In Vitro/In Vivo Translation by Overcoming Limitations of Potency Assays & Animal Models to Accelerate Clinic Progress
Principal Scientist, Sanofi
Chief Executive Officer, Abogen Biosciences
- What key factors should guide the selection of cell lines to develop bioassays that best predict in vivo LNP potency?
- How to design quantitative assays that measure relevant payload expression levels for understanding biological activity?
- Which animal models provide the most reliable assessment of LNP potency and how to better address variability in biodistribution and protein corona formation between species?
Formulation & Delivery
Process Development & Manufacturing
3:00 pm Afternoon Networking Break & Scientific Poster Session
Contribute to the conversation and share your cutting-edge research with your fellow LNP community to showcase your breakthrough discoveries to a vast audience of experts. Register your place to submit an abstract for review to showcase your poster.
Analytical Development & Characterization
Formulation & Delivery
Process Development & Manufacturing
Analytical Development & Characterization
Strengthening LNP Quality with Robust Analytical Strategies for Stability Testing
3:30 pm De-Risking LNP Stability through Advanced Analytical Strategies to Monitor Degradation & Optimize Shelf-Life
Principal Scientist, Tessera Therapeutics
- Identifying key degradation pathways and stress factors which impact LNP integrity
- Establishing reliable analytical methods to monitor stability of different LNP formulations
- Uncovering stability testing strategies to determine optimal storage conditions for extended shelf-life
NEW DATA
4:00 pm Session Reserved for Partner
Enquire at Sponsor@hansonwade.com
4:30 pm Turning Up the Heat: DSC Unveils the Hidden Links Between Lipid Structure & LNP Morphology
Scientist, Pfizer
- Thermal Profiling for Lipids: Learning how advanced thermal characterization techniques reveal the hidden resilience – or fragility – of LNPs under different storage temperatures
- Lipid Synergy & Stability Forecasting: Uncovering how lipidlipid interactions influence formulation robustness and enable smarter predictions of long-term LNP stability
- Tailoring Lipid Structure for RNA Therapeutics: Offering a predictive framework for designing effective mRNA/LNP formulations
NEW DATA
Formulation & Delivery
Process Development & Manufacturing